Evolution of treatment strategies for oligometastatic NSCLC patients – A systematic review of the literature

This publication has 42 references indexed in Scilit:

• Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
  Journal of Thoracic Oncology, 2013
• Stereotactic body radiotherapy for oligometastases
  The Lancet Oncology, 2013
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
  Clinical Cancer Research, 2012
• MicroRNA Expression Characterizes Oligometastasis(es)
  PLOS ONE, 2011
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
  The Lancet Oncology, 2011
• Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer
  Radiation Oncology, 2011
• Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review
  Journal of Thoracic Oncology, 2010
• Surgical Treatment of Non-Small Cell Lung Cancer with Isolated Synchronous Brain Metastases
  Journal of Korean Medical Science, 2006
• Successful treatment of solitary extracranial metastases from non—small cell lung cancer
  The Annals of Thoracic Surgery, 1995
• Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991
  Journal of Neurosurgery, 1995